ArticleOncotarget2017

ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.

Arjan Kol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.